Olanzapine Matches Dexmedetomidine for Delirium, Signals Lower Mortality
This single-center randomized trial directly compares oral olanzapine against low-dose intravenous dexmedetomidine for treating established ICU delirium, an area where efficacy data are scarce and guidelines remain noncommittal.
📅 Journal publication: Aug 1, 2026·Last updated: Sep 26, 2026
olanzapinedexmedetomidineantipsychoticsalpha-2 agonistsICU deliriumsedationcritical carerandomized controlled trialmortalityCAM-ICUCritical Care / ICU
Background Information
Olanzapine and dexmedetomidine offer dual options for ICU delirium management.
Managing delirium in critically ill patients can significantly affect outcomes, including length of ICU stay and overall recovery. The study found olanzapine and low-dose dexmedetomidine both effective for delirium, but with different side effect profiles. This study informs clinicians on alternative pharmacological strategies for ICU delirium, noting the potential side effects and efficacy of each option. Olanzapine and dexmedetomidine are effective for ICU delirium with varying side effect considerations.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Liu J, Wang C, Nie X, Yang R, Wang M, Ma X, Xu K, Wu G, Li D, Liu S
Citation:Liu J, Wang C, Nie X, et al. Olanzapine versus low-dose dexmedetomidine for delirium in patients with critical illness: a randomized clinical trial. American journal of respiratory and critical care medicine. 2026;212(8):1845-1848. doi:10.1093/ajrccm/aamag235